UBS Group’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-11,987
| Closed | -$7.07K | – | 10944 |
|
|
2024
Q4 | $7.07K | Sell |
11,987
-471
| -4% | -$327 | ﹤0.01% | 8501 |
|
|
2024
Q3 | $9.83K | Buy |
12,458
+405
| +3% | +$405 | ﹤0.01% | 7765 |
|
|
2024
Q2 | $15.3K | Buy |
12,053
+7,225
| +150% | +$9.55K | ﹤0.01% | 7475 |
|
|
2024
Q1 | $6.71K | Buy |
+4,828
| New | +$7.99K | ﹤0.01% | 7445 |
|
|
2023
Q4 | – | Sell |
-88
| Closed | -$125 | – | 10048 |
|
|
2023
Q3 | $125 | Buy |
+88
| New | +$135 | ﹤0.01% | 8832 |
|
|
2023
Q2 | – | Sell |
-1,640
| Closed | -$1.38K | – | 9829 |
|
|
2023
Q1 | $1.38K | Sell |
1,640
-1,170
| -42% | -$1.66K | ﹤0.01% | 8752 |
|
|
2022
Q4 | $3.99K | Buy |
+2,810
| New | +$4.64K | ﹤0.01% | 9407 |
|
|
2022
Q3 | – | Sell |
-793
| Closed | -$2K | – | 11074 |
|
|
2022
Q2 | $2K | Sell |
793
-1,498
| -65% | -$3.63K | ﹤0.01% | 9641 |
|
|
2022
Q1 | $7K | Sell |
2,291
-10,620
| -82% | -$37.1K | ﹤0.01% | 8860 |
|
|
2021
Q4 | $48K | Sell |
12,911
-27,003
| -68% | -$153K | ﹤0.01% | 6947 |
|
|
2021
Q3 | $269K | Buy |
39,914
+28,820
| +260% | +$225K | ﹤0.01% | 5109 |
|
|
2021
Q2 | $113K | Buy |
11,094
+10,396
| +1,489% | +$87K | ﹤0.01% | 5785 |
|
|
2021
Q1 | $6K | Buy |
+698
| New | +$5.82K | ﹤0.01% | 8259 |
|
UBS Group's CYTH Position: Q1 2025 in Review
UBS Group sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 11,987 shares — an estimated $7.07K sold.
UBS Group first reported a position in CYTH in Q1 2021 and held it in 13 quarters. The position peaked at $269K in Q3 2021. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.
- UBS Group reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- UBS Group sold 11,987 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $7.07K.
- UBS Group first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
- UBS Group's Cyclo Therapeutics, Inc. Common Stock position peaked at $269K in Q3 2021.
- 0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.
Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.